The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Dysgerminoma

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Dysgerminoma

 

High impact information on Dysgerminoma

  • CSF placental alkaline phosphatase as marker in cranial dysgerminoma [5].
  • PURPOSE: To review the outcome for all patients with ovarian dysgerminoma treated at the M.D. Anderson Cancer Center who received bleomycin, etoposide, and cisplatin (BEP) and to assess the menstrual and reproductive function of those who received conservative treatment [6].
  • The immunological nature of the increased 1,25(OH)2D3 production observed in dysgerminomas was further emphasized by correlation between expression of 1alpha-hydroxylase and the endotoxin recognition factors CD14 and toll-like receptor 4 (TLR4) [7].
  • We performed dual color fluorescence in situ hybridization (FISH) analyses with a centromeric alpha-satellite probe for chromosome 12 and a subtelomeric probe for 12p on paraffin-embedded tissue sections from 21 dysgerminomas and two gonadoblastomas [8].
  • Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications [9].
 

Chemical compound and disease context of Dysgerminoma

 

Biological context of Dysgerminoma

 

Anatomical context of Dysgerminoma

 

Gene context of Dysgerminoma

 

Analytical, diagnostic and therapeutic context of Dysgerminoma

References

  1. Immunohistochemical differences between intracranial germinomas and their gonadal equivalents. An immunoperoxidase study of germ cell tumors with epithelial membrane antigen, cytokeratin, and vimentin. Nakagawa, Y., Perentes, E., Ross, G.W., Ross, A.N., Rubinstein, L.J. J. Pathol. (1988) [Pubmed]
  2. OCT4: a novel biomarker for dysgerminoma of the ovary. Cheng, L., Thomas, A., Roth, L.M., Zheng, W., Michael, H., Karim, F.W. Am. J. Surg. Pathol. (2004) [Pubmed]
  3. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Werness, B.A., Ramus, S.J., Whittemore, A.S., Garlinghouse-Jones, K., Oakley-Girvan, I., Dicioccio, R.A., Tsukada, Y., Ponder, B.A., Piver, M.S. Hum. Pathol. (2000) [Pubmed]
  4. Neuron-specific enolase as a serum marker for immature teratoma and dysgerminoma. Kawata, M., Sekiya, S., Hatakeyama, R., Takamizawa, H. Gynecol. Oncol. (1989) [Pubmed]
  5. CSF placental alkaline phosphatase as marker in cranial dysgerminoma. Ramakrishnan, S., Manifold, I.H., Ward, A.M., Forster, D.M. Lancet (1989) [Pubmed]
  6. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. Brewer, M., Gershenson, D.M., Herzog, C.E., Mitchell, M.F., Silva, E.G., Wharton, J.T. J. Clin. Oncol. (1999) [Pubmed]
  7. Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Evans, K.N., Taylor, H., Zehnder, D., Kilby, M.D., Bulmer, J.N., Shah, F., Adams, J.S., Hewison, M. Am. J. Pathol. (2004) [Pubmed]
  8. Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis. Cossu-Rocca, P., Zhang, S., Roth, L.M., Eble, J.N., Zheng, W., Karim, F.W., Michael, H., Emerson, R.E., Jones, T.D., Hattab, E.M., Cheng, L. Mod. Pathol. (2006) [Pubmed]
  9. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Sever, M., Jones, T.D., Roth, L.M., Karim, F.W., Zheng, W., Michael, H., Hattab, E.M., Emerson, R.E., Baldridge, L.A., Cheng, L. Mod. Pathol. (2005) [Pubmed]
  10. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. Williams, S.D., Blessing, J.A., Hatch, K.D., Homesley, H.D. J. Clin. Oncol. (1991) [Pubmed]
  11. Differentiation potential of ovarian dysgerminoma: an immunohistochemical study of 15 cases. Lifschitz-Mercer, B., Walt, H., Kushnir, I., Jacob, N., Diener, P.A., Moll, R., Czernobilsky, B. Hum. Pathol. (1995) [Pubmed]
  12. Ovarian dysgerminoma associated with Pseudo-Meigs' syndrome and functioning ovarian stroma: a case report. Gücer, F., Oz-Puyan, F., Mülayim, N., Yüce, M.A. Gynecol. Oncol. (2005) [Pubmed]
  13. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Williams, S.D., Kauderer, J., Burnett, A.F., Lentz, S.S., Aghajanian, C., Armstrong, D.K. Gynecol. Oncol. (2004) [Pubmed]
  14. Fractal tumor growth of ovarian cancer: sonographic evaluation. Kikuchi, A., Kozuma, S., Sakamaki, K., Saito, M., Marumo, G., Yasugi, T., Taketani, Y. Gynecol. Oncol. (2002) [Pubmed]
  15. Microsatellite instability in gonadal tumors of XY pure gonadal dysgenesis patients. Funato, T., Uehara, S., Takahashi, M., Kozawa, K., Satoh, J., Sasaki, T., Kaku, M. Int. J. Gynecol. Cancer (2002) [Pubmed]
  16. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary. Suzuki, M., Kobayashi, H., Ohwada, M., Terao, T., Sato, I. Gynecol. Oncol. (1998) [Pubmed]
  17. Accumulation of gamma/delta T cells in human dysgerminoma and seminoma: roles in autologous tumor killing and granuloma formation. Zhao, X., Wei, Y.Q., Kariya, Y., Teshigawara, K., Uchida, A. Immunol. Invest. (1995) [Pubmed]
  18. Pure XY gonadal dysgenesis presenting as secondary amenorrhea. A case report. McClure, N., Henry, O., Harley, J.M. The Journal of reproductive medicine. (1992) [Pubmed]
  19. Dysgerminoma with a slightly elevated alpha-fetoprotein level diagnosed as a mixed germ cell tumor after recurrence. Aoki, Y., Kase, H., Fujita, K., Tanaka, K. Gynecol. Obstet. Invest. (2003) [Pubmed]
  20. Cellular differentiation in ovarian sex-cord-stromal and germ-cell tumors studied with antibodies to intermediate-filament proteins. Miettinen, M., Wahlstrom, T., Virtanen, I., Talerman, A., Astengo-Osuna, C. Am. J. Surg. Pathol. (1985) [Pubmed]
  21. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Baker, P.M., Oliva, E. Int. J. Gynecol. Pathol. (2005) [Pubmed]
  22. Transcription factors GATA-4 and GATA-6, and their potential downstream effectors in ovarian germ cell tumors. Mannisto, S., Butzow, R., Salonen, J., Leminen, A., Heikinheimo, O., Heikinheimo, M. Tumour Biol. (2005) [Pubmed]
  23. DNA cytometry of pure dysgerminomas of the ovary. Oud, P.S., Soeters, R.P., Pahlplatz, M.M., Hermkens, H.G., Beck, H.L., Reubsaet-Veldhuizen, J., Vooijs, G.P. Int. J. Gynecol. Pathol. (1988) [Pubmed]
  24. A monoclonal antibody that specifically reacts with human embryonal carcinomas, spermatogonia and oocytes is able to induce human EC cell death. Nakano, T., Umezawa, A., Abe, H., Suzuki, N., Yamada, T., Nozawa, S., Hata, J. Differentiation (1995) [Pubmed]
 
WikiGenes - Universities